Ozempic, glucagon, and 'newer versions': what this TikTok gets right and wrong

What did @healthresultsofficial actually say?

The creator made several distinct claims worth separating. First, that semaglutide works partly by inhibiting glucagon, which raises blood sugar, and that this effect helped resolve type 2 diabetes. Second, that the weight-loss version is "literally the same molecule" as the diabetes version, just at a higher dose with a new patent and name. Third, that this dose is "four or five times" higher. And fourth, that the primary mechanism at weight-loss doses amounts to "a paralysis of the intestines."

That last phrase is doing a lot of work. It sounds alarming, and whether it holds up scientifically is the crux of whether this video is useful or misleading for the 1,700 people who watched it.

Does the science back this up?

The glucagon piece is mostly accurate. The dose comparison is broadly correct but oversimplified. The intestinal paralysis framing is where things go sideways.

On glucagon: GLP-1 receptor agonists do suppress glucagon secretion from pancreatic alpha cells, not the liver directly (the caption's claim). This contributes to lower fasting glucose. That part is supported by the literature. Nauck et al. (2021, Diabetes Care) confirmed glucagon suppression as a meaningful mechanism alongside insulin secretion stimulation.

On dose: Ozempic is approved at 0.5 mg, 1 mg, and 2 mg weekly. Wegovy tops out at 2.4 mg weekly. That is a roughly 20% increase over the highest Ozempic dose, not four or five times. The creator appears to be conflating the starting dose of Ozempic (0.5 mg) with the maintenance dose of Wegovy (2.4 mg), which gets you to roughly a 4-5x ratio, but that comparison is misleading because patients do not stay at 0.5 mg long-term.

On gastroparesis-adjacent slowing: GLP-1 receptor agonists do delay gastric emptying. That is a real, documented effect. But calling it "paralysis of the intestines" misrepresents both the degree and the mechanism. Davies et al. (2021, The Lancet) noted gastric emptying delay as a contributing factor to satiety and nausea, not an intestinal paralysis event.

What did they get wrong (or right)?

Credit where it is due: the glucagon mechanism explanation is cleaner than most TikTok content on this topic, and the core idea that weight-loss versions of semaglutide are higher-dose formulations of the same molecule is directionally accurate.

But the errors matter. The caption says glucagon is "secreted from the liver." It is not. Glucagon is secreted by pancreatic alpha cells. The liver is where glucagon exerts its primary effect, stimulating glycogenolysis and gluconeogenesis. That is a meaningful distinction, not a minor slip.

"Paralysis of the intestines" as a description of gastric motility slowing is dramatic enough to be clinically irresponsible. True gastroparesis is a serious condition. Conflating delayed gastric emptying, which is a known, dose-dependent side effect, with intestinal paralysis will frighten patients who are candidates for these medications and misrepresent the risk profile. The creator acknowledged they were being dramatic. That disclaimer does not neutralize the framing.

The "own patent and now its own name" point implies something deceptive about the drug industry's practices. That framing is editorializing, not science, and it is worth naming as such.

What should you actually know?

Semaglutide is approved in two formulations for different indications: Ozempic for type 2 diabetes management and Wegovy for chronic weight management. They contain the same active molecule. The dose difference between the highest Ozempic dose and Wegovy's maintenance dose is approximately 20%, not 400-500%.

GLP-1 receptor agonists delay gastric emptying. This contributes to the nausea, vomiting, and feeling of fullness that are the most common side effects. Wilding et al. (2021, New England Journal of Medicine) reported that gastrointestinal side effects affected roughly 44% of participants on semaglutide 2.4 mg versus 16% on placebo. These are real, clinically significant effects. They are not intestinal paralysis.

If you are considering a GLP-1 receptor agonist for diabetes or weight management, the side effect profile is something to discuss with a clinician based on your personal history, including any prior history of gastroparesis or gastrointestinal conditions. TikTok videos, including this one, are not a substitute for that conversation.